Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds

177Lu-DOTATATE

  • Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of <sup>177</sup>Lu-DOTATATE PRRT: Does In Vivo Molecular PET Perform Better from the Viewpoint of Prediction of Tumor Biology?
    You have access
    Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of 177Lu-DOTATATE PRRT: Does In Vivo Molecular PET Perform Better from the Viewpoint of Prediction of Tumor Biology?
    Aadil Adnan and Sandip Basu
    Journal of Nuclear Medicine Technology September 1, 2022, 50 (3) 248-255; DOI: https://doi.org/10.2967/jnmt.121.261998
  • Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After <sup>177</sup>Lu-DOTATATE Infusion
    You have access
    Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After 177Lu-DOTATATE Infusion
    Sameer Tipnis, William J. Rieter, Vladimir Henderson-Suite and Leonie Gordon
    Journal of Nuclear Medicine Technology September 1, 2022, 50 (3) 274-277; DOI: https://doi.org/10.2967/jnmt.121.262820
  • You have access
    Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
    Diane K. Soulek, Molly E. Martin, Nic J. Mastascusa and Stephen A. Graves
    Journal of Nuclear Medicine Technology September 1, 2022, 50 (3) 195-202; DOI: https://doi.org/10.2967/jnmt.122.263813
  • You have access
    Combined 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option
    Aadil Adnan and Sandip Basu
    Journal of Nuclear Medicine Technology September 1, 2020, 48 (3) 292-294; DOI: https://doi.org/10.2967/jnmt.119.237354
  • You have access
    Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with 177Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy
    Aadil Adnan and Sandip Basu
    Journal of Nuclear Medicine Technology March 1, 2020, 48 (1) 36-39; DOI: https://doi.org/10.2967/jnmt.119.227058
  • You have access
    Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of 68Ga/177Lu-DOTATATE with Improvement of Vision
    Rahul V. Parghane and Sandip Basu
    Journal of Nuclear Medicine Technology June 1, 2019, 47 (2) 171-172; DOI: https://doi.org/10.2967/jnmt.118.217455
  • You have access
    Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
    Amanda Abbott, Christopher G. Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly Boyle, Matthew H. Kulke, Jennifer A. Chan, Heather A. Jacene and Annick D. Van den Abbeele
    Journal of Nuclear Medicine Technology September 1, 2018, 46 (3) 237-244; DOI: https://doi.org/10.2967/jnmt.118.209148
  • You have access
    Imaging-Guided Use of Combined 177Lu-DOTATATE and Capecitabine Therapy in Metastatic Mediastinal Paraganglioma
    Abhiram G. Ashwathanarayana, Chinmoy K. Biswal, Ashwani Sood, Ashwin S. Parihar, Rakesh Kapoor and Bhagwant R. Mittal
    Journal of Nuclear Medicine Technology December 1, 2017, 45 (4) 314-316; DOI: https://doi.org/10.2967/jnmt.117.197400
  • You have access
    177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function
    Rohit Ranade and Sandip Basu
    Journal of Nuclear Medicine Technology June 1, 2016, 44 (2) 65-69; DOI: https://doi.org/10.2967/jnmt.115.168146
  • You have access
    Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
    Sandip Basu and Rohit Ranade
    Journal of Nuclear Medicine Technology June 1, 2016, 44 (2) 85-87; DOI: https://doi.org/10.2967/jnmt.115.163527

Pages

  • Next
  • 1
  • 2
SNMMI

© 2025 SNMMI

Powered by HighWire